



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

llan et al

Serial No.

10/676,045

Group Art Unit: Not yet determined

Filed:

September 30, 2003

Examiner: Not yet determined

Title:

EDUCATED NKT CELLS AND THEIR USES IN THE TREATMENT OF IMMUNE-

RELATED DISORDERS

TRANSMITTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Information Disclosure Statement which is being filed in accordance with 37 C.F.R. §§ 1.56 and 1.97-1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No.: EL701001103US Deposit Date: January 26, 2004

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.110 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ronald C. Fedus

Reg. No. 32,567

01/29/2004.WABBELR1.00000146.051135 ...10676045

01 FC:1460

130.00 DA





For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

	item is	s enclosed:
2. []	that is	ach of the following items listed on the enclosed copy of form PTO-1449 not in the English language, a concise explanation of the relevance of em is incorporated in the specification of the above-identified ation.
3. []	enclos or sub	opy of the items on the enclosed copy of Form PTO-1449 that is not sed with this Information Disclosure Statement was previously cited by emitted to the Patent and Trademark Office in the prior [] Divisional or ntinuation-In-Part application under 37 C.F.R. §1.60, U.S. Serial No, filed
4. []		e is due under 37 C.F.R. §1.17(p) for this Information Disclosure ment since it is being filed in compliance with:
	[]	37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application.
	[]	37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in ∍1.491 in an international application.
	[]	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits.
5. []	Stater the perfinal a action	e is due under 37 C.F.R. §1.17(p) for this Information Disclosure ment since it is being filed in compliance with 37 C.F.R. §1.97(c), after eriod specified in paragraph 4 above but before the mailing date of a ction or a Notice of Allowance (where there has been no prior final), and is accompanied by one of the certifications pursuant to 37 C.F.R. (e) set forth in paragraph 9 below.
6. [x]	Stater the pe	is due under 37 C.F.R. §1.17(p) for this Information Disclosure ment since it is being filed in compliance with 37 C.F.R. §1.97(c), after priod specified in paragraph 4 above but before the mailing date of a ction or a notice of allowance (where there has been no prior final):
	[]	A check in the amount of \$180.00 is enclosed in payment of the fee.



- [x] Charge the fee to Deposit Account No. 05-1135, Order No. Enz-63(CIP). A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- 7. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
 - a. one of the certification pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
 - the attached petition requesting consideration of this Information
 Disclosure Statement; and
 - c. the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
- 8. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
 - a. [] 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
 - b. [] 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue.
 - c. [] The fee due under 37 C.F.R §1.17(i)(1) is paid as set forth in paragraph 10 below.
- 9. [] I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
 - [] I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- 10. [] A check in the amount of \$180.00 is enclosed in payment of the fee due under 37 C.F.R. §1.17(i)(1).
 - [X] Charge the fee under 37 C.F.R. §1.17(i)(1) to Deposit Account No. 05-1135. Order No. Enz-63(CIP). A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
 - [x] The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 05-1135. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

Dated: January 26, 2004

Ronald C. Fedus

Registration No. 32,567

Natalie Bogdanos

Registration No. <u>51,480</u> Attorneys for Applicants

Mailing Address:

ENZO LIFE SCIENCES, INC. c/o Enzo Biochem, Inc. 292 Madison Avenue, 9th Floor New York, New York 10022 Telephone: (212) 583-0100

Telefax: (212) 583-0150



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ilan et al

Serial No.

10/676,045

Group Art Unit: Not yet known

Filed:

September 30, 2003

Examiner: Not yet known

Title: EDUCATED NKT CELLS AND THEIR USES

IN THE TREATMENT OF IMMUNE-RELATED)

DISORDERS

527 Madison Avenue, 9th Floor New York, New York 10022 January 26, 2004

FILED VIA EXPRESS MAIL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.56 & 1.971.98

Dear Sirs:

Pursuant to the provisions of 37 C.F.R. §§1.971.98, and in full compliance with their duty of disclosure under 37 C.F.R. §1.56, Applicants, through their attorney, are bringing the following one-hundred-thirty (130) documents to the attention of the U.S. Patent and Trademark Office and the Examiner handling their above-identified application:

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 2 [Information Disclosure Statement

- January 26, 2004]

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No.: <u>EL701001103US</u> Deposit Date: <u>January 26, 2004</u>

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.110 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandra, VA 22313-1450.

Ronald C. Fedus

Reg. No. 32,567

2004

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 3 [Information Disclosure Statement

– January 26, 2004]

- 1. Adorini, L., et al., "Pathogenesis and immunotherapy of autoimmune diseases," lmmunol. Today 18:209-211 (1997) [Exhibit 1];
- 2. Arase, H., et al., "NK1.1 + CD4 + CD8- thymocytes with specific lymphokine secretion," <u>Eur. J. Immunol.</u> 23:307-310 (1993) [Exhibit 2];
- 3. Arase, H., et al., "Interferon gamma production by natural killer (NK) cells and NK1.1 + T cells upon NKR-P1 cross-linking," <u>J. Exp. Med. 183</u>:2391-2396 (1996) [Exhibit 3];
- 4. Arase, H., et al., "Lymphokine-activated killer cell activity of CD4-CD8- TCR alpha beta + thymocytes," J. Immunol. 151:546 (1993) [Exhibit 4];
- 5. Ballas, Z.K., et al., "Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1 + CD8 alpha + beta- TCR-alpha beta B220 + lymphokine-activated killer subset," J. Immunol. 150:17-30 (1993) [Exhibit 5];
- 6. Bendelac, A., et al., "MOUSE CD1-SPECIFIC NK1 T CELLS: Development, Specificity, and Function," <u>Annu. Rev. Immunol.</u> 15:535-562 (1997) [Exhibit 6];
- 7. Bendelac, A., et al., "Mouse NK1 + T cells," <u>Curr. Opin. in Immunol. 7</u>:367-374 (1995) [Exhibit 7];
- 8. Blanas, E., et al., "Induction of Autoimmune Diabetes by Oral Administration of Autoantigen," <u>Science 274</u>:1707-1709 (1996) [Exhibit 8];
- 9. Bleicher, P.A., et al., "Expression of murine CD1 on gastrointestinal epithelium," <u>Science 250</u>:679-682 (1990) [Exhibit 9];
- 10. Callery, M.P., et al., "The effect of portacaval shunt on delayed-hypersensitivity responses following antigen feeding," <u>J. Surg. Res. 46</u>:391-394 (1989) [Exhibit 10];
- 11. Carvalho, C.R., et al., "Indirect effects of oral tolerance cannot be ascribed to bystander suppression," <u>Scand. J. Immunol. 45</u>:276-281 (1997) [Exhibit 11];
- 12. Chen, H., et al., "Cultured NK1.1 + CD4 + T cells produce large amounts of IL-4 and IFN- gamma upon activation by anti-CD3 or CD1," <u>J. Immunol.</u> 159:2240-2249 (1997) [Exhibit 12];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 4 [Information Disclosure Statement

- 13. Chiba, M., et al., "Human colonic intraepithelial and lamina proprial lymphocytes: cytotoxicity in vitro and the potential effects of the isolation method on their functional properties," Gut 22:177-182 (1981) [Exhibit 13];
- 14. Coligan, J.E., et al., *Current Protocols in Immunology*, Wiley and Sons (1994) [Exhibit 14];
- 15. Collins, C., et al., "RAG1, RAG2 and pre-T cell receptor alpha chain expression by adult human hepatic T cells: evidence for extrathymic T cell maturation," <u>Eur. J. Immunol.</u> 26:3114-3118 (1996) [Exhibit 15];
- 16. Crispe, I.N., et al., "Strange brew: T cells in the liver," lmmun. Today 17:522-525 (1996) [Exhibit 16];
- 17. Crispe, I.N., et al., "The liver as a site of T-cell apoptosis: graveyard, or killing field?," Immunol. Review 174:47-62 (2000) [Exhibit 17];
- Cui, J., et al., "Inhibition of T Helper Cell Type 2 Cell Differentiation and Immunoglobulin E Response by Ligand-activated Vα14 Natural Killer T Cells," J. Exp. Med. 190(6):783-792 (1999) [Exhibit 18];
- 19. Das, K.M., et al., "A shared and unique epitope(s) on human colon, skin and biliary epithelium detected by a monoclonal antibody," <u>Gastroenterology</u> 98:464-69 (1990) [Exhibit 19];
- 20. Dasgupta, A., et al., "Circulating immunoglobulin G1 in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody," <u>Gut 35</u>:1712-1717 (1994) [Exhibit 20];
- 21. David, G.S., et al., United States Patent No. 4,376,110, filed August 4, 1980 [Exhibit 21];
- 22. Doherty, D.G., et al., "Distinct cytotoxic lymphocytes subsets suggest a role for the liver in immune homeostasis," <u>J. Hepatology 28</u>:59 (1998) [Exhibit 22];
- 23. Doherty, D.G., et al., "Human lymphocytes with dual T cell and natural killer cell phenotype and function in the normal adult liver," Hepatology 26:445A (1997) [Exhibit 23];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 5 [Information Disclosure Statement

January 26, 2004]

- 24. Garcia-Barcina, M., et al., "Detection of cell-adhesion molecules on human liver-associated lymphocytes," Immunol. 82:95-98 (1994) [Exhibit 24];
- 25. Hancock, W., et al., "Suppression of InsuliItis in Non-Obese Diabetic (NOD) Mice by Oral Insulin Administration Is Associated with Selective Expression of Interleukin-4 and -10, Transforming Growth Factor-β, and Prostaglandin-E," Am. J. Path. 147(5):1193-1197 (1995) [Exhibit 25];
- 26. Hashimoto, W., et al., "Cytotoxic NK1.1 Ag + alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12," J. Immunol. 154:4333-4340 (1995) [Exhibit 26];
- 27. Hayakawa, T., et al., "Murine thymic CD4+ T cell subsets: a subset (Thy0) that secretes diverse cytokines and overexpresses the V beta 8 T cell receptor gene family," J. Exp. Med. 176:269-274 (1992) [Exhibit 27];
- 28. Hibi, S., et al., "Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis," <u>Clin. Exp. Immunol. 54</u>:163-168 (1983) [Exhibit 28];
- 29. Ilan, Y., et al., "Treatment of experimental colitis through induction of oral tolerance towards colitis-extracted proteins," <u>Gastro 114</u>:260 (1998) [Exhibit 29];
- 30. Jonsson, J.R., et al., "Expression of FAS/FASL and BCL-2 in normal human liver derived leucocytes," Hepatology 26:269A (1997) [Exhibit 30];
- 31. Kawamura, T., et al., "Cutting Edge: Critical Role of NK1 + T Cells in IL-12-Induced Immune Responses In Vivo," J. Immunol. 160:16-19 (1998) [Exhibit 31];
- 32. Kitamura, H., et al., "The Natural Killer T (NKT) Cell Ligand ∞
 Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells," J. Exp. Med. 189:1121-1127 (1999) [Exhibit 32];
- 33. Kohler, G., et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature 256:495-497 (1975) [Exhibit 33];
- 34. Kuhn, R., et al., "Interleukin-10-deficient mice develop chronic enterocolitis," Cell 75:263-274 (1993) [Exhibit 34];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 6 [Information Disclosure Statement

- 35. Leite-De-Moraes, M.C., et al., "IL-4-producing NK T cells are biased towards IFN-gamma production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells," <u>Eur. J. Immunol. 28</u>:1507-1515 (1998) [Exhibit 35];
- 36. Ma, X., et al., "The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells," J. Exp. Med. 183:147-157 (1996) [Exhibit 36];
- 37. Mabuchi, A., et al., "Role of the liver in T cell differentiation--generation of CD3-CD4+/CD8+TCRbeta- cells and CD3-4-8-TCRbeta+ cells from CD4-8-TCRbeta- athymic nude bone marrow cells by culture with parenchymal liver cells," J. Leukocyte Biology 63:575-583 (1998) [Exhibit 37];
- 38. MacDonald, R.H., "NK1.1 + T cell receptor-alpha/beta + cells: new clues to their origin, specificity, and function," <u>J. Exp. Med. 182</u>:633-638 (1995) [Exhibit 38];
- 39. Madsen, K.L., et al., "Interleukin 10 prevents cytokine-induced disruption of T84 barrier integrity and limits chloride secretion," <u>Gastroenterology</u> 113:151-159 (1997) [Exhibit 39];
- 40. Marth, T., et al., "High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis," <u>J. Immunol. 157</u>:2348-2357 (1996) [Exhibit 40];
- 41. Matzinger, P., "Tolerance, danger, and the extended family," <u>Ann. Rev. Immunol. 12</u>:991-1045 (1994) [Exhibit 41];
- 42. Mizoguchi, A., et al., "Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease," J. Exp. Med. 183:847-856 (1996) [Exhibit 42];
- 43. Murch, S.H., et al., "Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease," <u>Gut 34</u>:1705 (1998) [Exhibit 43];
- 44. Nakano, Y., et al., "Permanent acceptance of liver allografts by intraportal injection of donor spleen cells in rats," <u>Surgery 111</u>:668-676 (1992) [Exhibit 44];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 7 [Information Disclosure Statement

- 45. Neurath, M.F., et al., "Antibodies to interleukin 12 abrogate established experimental colitis in mice," <u>J. Exp. Med. 182</u>:1281-1290 (1995) [Exhibit 45];
- 46. Neurath, M., et al., "Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance," J. Exp. Med. 183:2605-2616 (1996) [Exhibit 46];
- 47. Once, Y., et al., "Involvement of both donor cytotoxic T lymphocytes and host NK1.1 + T cells in the thymic atrophy of mice suffering from acute graft-versus-host disease," Immunology 95:248-256 (1998) [Exhibit 47];
- 48. Parronchi, P., et al., "Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease," <u>Am. J. Pathol.</u> 150:823-832 (1997) [Exhibit 48];
- 49. Podolsky, D.K., et al., "Inflammatory bowel disease," New Engl. J. Med. 325:928-935 (1991) [Exhibit 49];
- 50. Pouwels, P.H., et al., *Cloning Vectors, A Laboratory Manual, Elsevier, New York* (1985) [Exhibit 50];
- 51. Powrie, F., et al., "Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4 + T cells," <u>Immunity</u> 1:553-562 (1994) [Exhibit 51];
- 52. Qin, S., et al., "'Infectious' Transplantation Tolerance," <u>Science 259</u>:974-977 (1993) [Exhibit 52];
- 53. Rabbani, E., et al., European Patent Application No. 1 149 586 A1, filed April 27, 2001 [Exhibit 53];
- 54. Raedler, A., et al., "Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors," Clin. Exp. Immunol. 60:518-526 (1985) [Exhibit 54];
- 55. Rodriquez, R.L., et al., *Vectors: A Survey of Molecular Cloning Vectors and their Uses, Butterworth-Heinemann, Boston (1987)* [Exhibit 55];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 8 [Information Disclosure Statement

- For the second s
- 57. Sadlack, B., et al., "Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene," Cell 75:253-261 (1993) [Exhibit 57];
- 58. Sander, J.H., et al., "Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group,"

 <u>Gastroenterology 113</u>:383-89 (1997) [Exhibit 58];
- 59. Seder, R.A., et al., "Acquisition of Lymphokine-Producing Phenotype by CD4+ T Cells," Annu. Rev. Immuno. 12:635-673 (1994) [Exhibit 59];
- 60. Seder, R.A., et al., "Interleukin 12 Acts Directly on CD4+ T Cells to Enhance Priming for Interferon Production and Diminishes Interleukin 4 Inhibition of Such Priming," Proc. Natl. Acad. Sci. USA 90:10188-10192 (1993) [Exhibit 60];
- 61. Seki, S., et al., "Unusual alpha beta-T cells expanded in autoimmune lpr mice are probably a counterpart of normal T cells in the liver," <u>J. Immunol.</u> 147:1214-1221 (1991) [Exhibit 61];
- 62. Sellon, R.K., et al., "Resident Enteric Bacteria are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice," <u>Infection and Immunity</u> 66:5224-5231 (1998) [Exhibit 62];
- 63. Strober, W., et al., "Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation," lmmunol.today 18:61-64 (1997) [Exhibit 63];
- 64. Strober, W., et al., *In Clinical Immunology*, Mosby, St. Louis, pp. 1401-1428 (1995) [Exhibit 64];
- 65. Takahashi, F., et al., "Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis," J. Clin. Invest. 76:311-318 (1985) [Exhibit 65];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 9 [Information Disclosure Statement

January 26, 2004]

- 66. Takahashi, M., et al., "LPS induces NK1.1+ alpha beta T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells," <u>J. Immunol. 156</u>:2436-2442 (1996) [Exhibit 66];
- 67. Telemo, E., et al., "Oral tolerance in experimental animals," Int. Arch. Allergy Immunol. 113:219-223 (1997) [Exhibit 67];
- 68. Trop, S., et al., "Liver-Associated Lymphocytes Expressing NK1.1 Are Essential for Oral Immune Tolerance Induction in a Murine Model," Hepatology 29:746-755 (1999) [Exhibit 68];
- 69. Vicari, A.P., et al., "Mouse NK1.1 + T cells: a new family of T cells," <u>Immunology Today 17(2)</u>:71 (1996) [Exhibit 69];
- 70. Von Herrath, M.G., et al., "Oral Insulin Treatment Suppresses Virus-induced Antigen-specific Destruction of β Cells and Prevents Autoimmune Diabetes in Transgenic Mice," J. Clin. Inves. 98:1324-1331 (1996) [Exhibit 70];
- 71. Wahl, et al., "Improved radioimaging and tumor localization with monoclonal F(ab')2," <u>J. Nucl. Med. 24</u>:316-325 (1983) [Exhibit 71];
- 72. Weiner, H., et al., "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> 12:809-837 (1994) [Exhibit 72];
- 73. Weiner, H., et al., "Oral Tolerance," <u>Proc. Natl. Acad. Sci. USA 91</u>:10762-10765 (1994) [Exhibit 73];
- 74. Weiner, H.L., et al., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," lmmunol. Today 18:335-343 (1997) [Exhibit 74];
- 75. Weiner, H.L., et al., "Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis," <u>Science 259</u>:1321-1324 (1993) [Exhibit 75];
- 76. Yoshimoto, T., et al., "CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3," J. Exp. Med. 179:1285-1295 (1994) [Exhibit 76];
- 77. Yoshimoto, T., et al., "Role of NK1.1 + T Cells in a TH2 Response and in Immunoglobulin E Production," <u>Science 270</u>:1845-1847 (1995) [Exhibit 77];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 10 [Information Disclosure Statement

- 78. Yu, S.Y., et al., "Portal vein administration of donor cells promotes peripheral allospecific hyporesponsiveness and graft tolerance," <u>Surgery 116</u>:229-234 (1994) [Exhibit 78];
- 79. Angulo, P., "Nonalcoholic fatty liver disease," New England J. of Medicine 346:1221-1231 (2002) [Exhibit 79];
- 80. Caldwell, S.H., et al., "Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease," <u>Hepatology 29</u>:664-669 (1999) [Exhibit 80];
- 81. Chandra, R.K., et al., "Immunocompetence in obesity," <u>Acta Paediatr. Scand.</u> 69:25-30 (1980) [Exhibit 81];
- 82. Cohen, B., et al., "Modulation of Insulin Activities by Leptin," <u>Science</u> 274:1185 (1996) [Exhibit 82];
- 83. Cortez-Pinto, H., et al., "Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study," <u>JAMA 282</u>:1659-1664 (1999) [Exhibit 83];
- 84. Diehl, A.M., et al., "Nonalcoholic Steatosis and Steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines," <u>J. Physiol. Gastrointerest. Liver Physiol 282</u>:G1-G5 (2002) [Exhibit 84];
- 85. Faggioni, R., et al., "Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: Role of tumor necrosis factor α and IL-18," Proc. Natl. Acad. Sci. USA 97:2367-2372 (2000) [Exhibit 85];
- 86. Feingold, C.T., et al., "Role of cytokines in inducing hyperlipidemia," <u>Diabetes 41(Suppl 2)</u>:97-101 (1992) [Exhibit 86];
- 87. Ferrara, J.L.M., et al., "Graft-versus-host disease," <u>New Neg. J. of Med.</u> 324:667-672 (1991) [Exhibit 87];
- 88. Field, C.J., et al., "Changes in circulating leukocytes and mitogen responses during very-low- energy all-protein reducing diets," <u>Am. J. Clin. Nutr.</u> 54:123-129 (1991) [Exhibit 88];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 11 [Information Disclosure Statement

- 89. George, D.K., et al., "Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis," <u>Gastroenterology</u> 114:311-318 (1998) [Exhibit 89];
- 90. Godfrey, D.J., et al., "NKT cells: Facts, functions and fallacies," <u>Immunol.</u> Today 21:573-583 (2000) [Exhibit 90];
- 91. Harrison, S.A., et al., "Vitamin E and Vitamin C in the Treatment of Nonalchoholic Steatohepatitis. A Prospective, Randomized, Placebo-Controlled Clinical Trial. A Preliminary Report," Gastroenterology 123:M1332 (2002) [Exhibit 91];
- 92. Hotamisligil, G.S., et al., "Adipose expression of tumor necrosis factor-[alpha]: direct role in obesity-linked insulin resistance," <u>Science 259</u>:87-91 (1993) [Exhibit 92];
- 93. Hotamisligil, G.S., "The role of TNFalpha and TNF receptors in obesity and insulin resistance," <u>J. Internal Med. 245</u>:621-625 (1999) [Exhibit 93];
- 94. Howard, J.K., et al., "Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in *ob/ob* mice," <u>J. Clin. Invest.</u> 104:1051-1059 (1999) [Exhibit 94];
- 95. Hruszkewycz, A.M., et al., "Evidence for mitochondrial DNA damage by lipid peroxidation," <u>Biochem. Biophys. Res. Commun. 153</u>:191-197 (1988) [Exhibit 95];
- 96. Ilan, Y., et al., U.S. Patent Application No. 10/451,811 filed June 25, 2003, a 371 of International Patent Application No. PCT/IL01/01197, subsequently published as WO 02/051986 on July 4, 2002; published version provided herein [Exhibit 96];
- 97. Koffler, M., et al., "Immunobiological consequence of regulation of insulin receptor on alloactivated lymphocytes in normal and obese subjects,"

 <u>Diabetes 40</u>:364-370 (1991) [Exhibit 97];
- 98. Krishnan, E., et al., "Study of function and maturation of monocytes in morbidly obese individuals," <u>J. Surg. Res. 33</u>:89-97 (1982) [Exhibit 98];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 12 [Information Disclosure Statement

- 99. Li, Z., et al., "Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system," Gastroenterology 123:1304-1310 (2002) [Exhibit 99];
- 100. Loffreda, S., et al., "Leptin regulates proinflammatory immune responses," FASEB J 12:57-67 (1998) [Exhibit 100];
- 101. Lord, G.M., et al., "Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression," <u>Nature 394</u>:897-901 (1998) [Exhibit 101];
- 102. Mattacks, C.A., et al., "Interactions of noradrenalin and tumour necrosis factor alpha, interleukin 4 and interleukin 6 in the control of lipolysis from adipocytes around lymph nodes," Cytokine 11:334-346 (1999) [Exhibit 102];
- 103. Matteoni, C.A., et al., "Nonalcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological Severity," <u>Gastroenterology</u> 116:1413 (1999) [Exhibit 103];
- 104. Mitchell, D.G., et al., "Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms and humans: fatty liver," Invest-Radiol.26:1041-1052 (1991) [Exhibit 104];
- 105. Montague, C.T., et al., "Depot-related gene expression in human subcutaneous and omental adipocytes," <u>Diabetes 47</u>:1384-1391 (1998) [Exhibit 105];
- 106. Nagler, A., et al., "Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model," <u>Bone Marrow Transplantation 32</u>:363-369 (2003) [Exhibit 106];
- 107. Ogawa, H., et al., "Cachectin/tumor necrosis factor and interleukin-1 show different modes of combined effect on lipoprotein lipase activity and intracellular lipolysis in 3T3-L1 cells," <u>Biochimica et Biophysica Acta 1003</u>:131-135 (1989) [Exhibit 107];
- 108. Pellymounter, M.A., et al., "Effects of the obese gene product on body weight regulation in ob/ob mice," <u>Science 269</u>:540-543 (1995) [Exhibit 108];

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 13 [Information Disclosure Statement

- 109. Pond, C.M., et al., "Long-term changes in adipose tissue in human disease," Proc. Nutr. Soc. 60:365-374 (2001) [Exhibit 109];
- 110. Purohit, A., et al., "Aromatase activity and interleukin-6 production by normal and malignant breast tissues," <u>J. Clin. Endocr. & Metab. 80</u>:3052-3058 (1995) [Exhibit 110];
- 111. Rosen, B.S., et al., "Adipsin and complement factor D activity: an immune-related defect in obesity," <u>Science 244</u>:1483-1487 (1989) [Exhibit 111];
- 112. Roy-Chowdhury, et al., U.S. Patent Application No. 08/808,629 filed February 28, 1997, with continuing applications No. 10/377,628 filed March 4, 2003 and 10/377,603 filed March 4, 2003, and divisional application no. 09/447,704 filed November 23, 1998, provided herein as reference [Exhibit 112];
- 113. Sanyal, A.J., et al., "Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities," <u>Gastroenterology 120</u>:1183-1192 (2001) [Exhibit 113];
- 114. Sarraf, P., et al., "Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia," <u>J. Exp. Med.</u> 185:171-175 (1997) [Exhibit 114];
- 115. Shilobet, O., et al., "NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells," <u>Int. J. Cancer</u> 106:236-243 (2003) [Exhibit 115];
- 116. Taylor, P.A., et al., "The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality," Blood 99:3493-3499 (2002) [Exhibit 116];
- 117. Tomohiro, N., et al., "Adrenal Masses: Quantification of Fat Content with MR Images," Radiology 218:642-646 (2001) [Exhibit 117];
- 118. Trop, S., et al., "NK 1.1 + T Cell: A Two-Faced Lymphocyte in Immune Modulation of the IL-4/IFN- Paradigm," J. Clin. Immunol. 22:270-280 (2002) [Exhibit 118];

lian et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 14 [Information Disclosure Statement

- January 26, 2004]

- 119. Uysal, K.T., et al., "Protection from obesity-induced insulin resistance in mice lacking Tnf-alpha function," Nature 389:610-614 (1997) [Exhibit 119];
- 120. Vogelsang, G.B., et al., "Graft versus host disease: Implications from basic immunology for prophylaxis and treatment," <u>Cancer Treat. Res. 77</u>:87-97 (1997) [Exhibit 120];
- 121. Yang, et al., "Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis," Proc. Natl. Acad. Sci_USA_94:2557-2562 (1997) [Exhibit 121];
- 122. Zeng, D., et al., "Bone Marrow NK1.1" and NK1.1 + T Cells Reciprocally Regulate Acute Graft versus Host Disease," <u>J. Exp. Med. 189</u>:1073-1081 (1999) [Exhibit 122];
- 123. Zhang, Y., et al., "Positional cloning of the mouse obese gene and its human homologue," Nature 372:425-432 (1994) [Exhibit 123];
- 124. Burdin, N., et al., "Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis," <u>Eur J. Immunol.</u> 29:2014-2025 (1999) [Exhibit 10];
- 125. Gotsman, I., et al., "Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1.," <u>Transplant Proc. 32</u>:749-750 (2000) [Exhibit 125];
- 126. Levinson, D.A., U.S. Patent No. 5,721,351, filed June 7, 1995 [Exhibit 126];
- 127. Levinson, D.A., U.S. Patent No. 6,066,498, filed June 7, 1995 [Exhibit 127];
- 128. Levinson, D.A., U.S. Patent No. 6,066,322, filed March 3, 1995 [Exhibit 128];
- 129. Shlomai, A., et al., "Immunomodulation of experimental colitis: the role of NK1.1 liver lymphocytes and surrogate antigens bystander effect," <u>J. Pathology 195</u>:498-507 (2001) [Exhibit 129];

>

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 15 [Information Disclosure Statement

January 26, 2004]

130. Sredni, B., et al., "Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101," <u>J. Natl. Cancer Inst. 88</u>:1276-1284 (1996) [Exhibit 130];

The first one-hundred-twenty-three (123) foregoing references (numbers 1-123) were cited in the specification of the instant application.

The seven (7) subsequent references (numbers 124-130) were cited in the International Search Report dated May 22, 2002 of the parent PCT Application (Publication No. WO 02/051986, published July 4, 2002).

A completed Form PTO-1449 listing the 130 above-submitted documents is also attached hereto as Exhibit 131.

By this voluntary citation of art, Applicants and their attorney are requesting that the documents be made of record in the present application.

The above citation of documents is not a representation that these documents constitute a complete or exhaustive listing, nor that the above listing necessarily includes the closest or most relevant documents, nor are these documents necessarily a complete listing of all documents known to Applicants or their attorney. It is simply a voluntary citation of documents made in good faith, which is not intended to serve in any way as a substitute for the Examiner's own search.

In view of the general and specific features described and claimed in the present application, Applicants respectfully submit that the present invention is neither disclosed nor suggested by the documents referred to above and is thus patentably distinct thereover. Furthermore, Applicants do not believe, and do not submit, by the citation of these references, that these documents, either by themselves or in combination with other documents, render the invention *prima facie* obvious under the duty of disclosure rules.

Applicants respectfully request that the Examiner make the above-submitted documents of record in the instant application. Applicants further request that the

llan et al

Serial No.: 10/676,045 Filed: September 30, 2003

Page 16 [Information Disclosure Statement

- January 26, 2004]

Examiner consider these documents as any of them may relate to the instant application.

The fee under 37 C.F.R. §1.17(p) for filing this Information Disclosure Statement is \$180.00. The Patent and Trademark Office is hereby authorized to charge the amount of this fee (and any other fees in connection with this IDS) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

Respectfully submitted,

Ronald C. Fedus

Registration No. 32,567

Natalie Bogdanos

Registration No. 51,480 Attorneys for Applicants

ENZO LIFE SCIENCES, INC. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, New York 10022 Tel. (212) 583-0100

										·	Sheet	<u>1</u> 0	f <u>13</u>	
Form PTO-1	449 1	J.S. [Depai	rtmer	nt of	Com	merc	e	Atty. C ENZ-6	Oocket No.	Serial	No. 10/	676,045	j .
(REV. 8-83)	Pate	nt an	d Tra	adem	ark (Office)		1112-0	(CIF)				
	RMAT								-					
OIPE	ise se	veral	shee	ts if	neces	ssary)						<u>/</u>	
,	CYS								Applica	ants: llan, et al	-			
JAN 2 6 2004	ابع							•	F:) 1			•		
), ,								•	Filed:	Sep. 30, 2003	Group	o: Not y	et know	'n
TRADEMA	*/						U.S.	PATI	NT DOCU	MENTS				
						· · · · ·				,			FILING	
EXAMINER												SUB	DATE	
INITIAL		ро	CUM	IENT	NUN	1BER			DATE	NAME	CLASS	CLASS	PRIAT	
		4	3	7	6	1	1	0		David, et al.				
		0	1	7	0	2	5	8	2003	Roy-Chowdhury et al.	,			
		5	7	2	1	3	5	1		Levinson		 	 	
		6	0	6	6	4	9	8		Levinson	-	+	 	
	-	6	0	6	6	2	<u> </u>	-					ļ	
		0	١٠	0	0	3	2	2		Levinson				
	1	1				FC	DREIC	GN PA	TENT DO	CUMENTS	•			
									-				TRANS	S-
												SUB	LATIO	
		DO	CUM	IENT	NUN	1BER			DATE	NAME	CLASS	CLASS	YES	NO
	EP .	1	1	4	9	5	8	6		Rabbani, et	A1			
	wo	0	5	1	9	8	6		2002	llan, et al				
	l	OTH	I IER C	ocu	IMEN	I ITS (I Inclu	I ding /	। Author, Tit	l le, Date, Pertinent	Pages, E	itc.)	l I	
		Ado	rini, l	L., et	al.,	"Path	nogei			notherapy of autoin			Immuno	<u>)l.</u>
 					9-211			CD4 I	CDQ +b.	mocytes with spe	-if:- 1	la atria a a		
								0 (19		mocytes with spe	cine lymp	nokine si	ecretion,	•
		Aras	se, H	., et	al., "	Inter	feron	gami	ma produc	tion by natural kill			IK1.1+	T
	-									ed. 183:2391-239 er cell activity of (
									tivated kili 46 (1993)	er cen activity of (JU4-CD8-	- ICR aip	na peta	+
		Balla	s, Z	.К., е	t al.,	"Lyı	mpho	kine-	activated k	killer cells. VII. IL-4				•
					TCR-: 993)		beta	a B22	0 + lymph	okine-activated kill	er subset	t," <u>J. Imn</u>	nunol.	
 		_					10US	E CD	1-SPECIFIC	C NK1 T CELLS: D	evelonme	nt Speci	ficity a	nd
									<u>15:535-56</u>				, ai	
		Bend	delac	, A.,	et al	., "N	louse	NK1	+ T cells,	" Curr. Opin. in Im	munol. 7	:367-374	(1995)	
									utoimmune 07-1709 (Diabetes by Oral	Administ	ration		
EXAMINER		<u> </u>	atoa	nuge	, i, <u>s</u>	CICIL	UG Z.		DATE CO			·		
*FXAMINIFO	lniti	al if o	itatio	n cc	neid	ared	who	thera	r not sites	ion is in conforma	200 11124	MDED 60	Q. Dra	
line through	citatio	on if r	not in	i can	form	ance	and	not c	n not citat onsidered	Include copy of t	his form	with nevt	ع, Diaw	
communicat														

								_					Sheet	2 (of <u>13</u>	3
Form PTO-14	149 L	J.S. [Depar	tmer	nt of	Com	merc	е	ر	1	Docket No.		Seria	l No. 10	/676,0)45
(REV. 8-83)	Pate	nt an	d Tra	adem	ark (Office	•			ENZ-0	33(CIP)		}			
INITO	314A T		2100		IDE .	O17 4 :	T101			i						
INFOR	RMAT se se												1			
01. 5.	Ć,						•			Applic	ants: llan, et al		J			
2 6 2004	*				-									*		
	i i									Filed:	Sep. 30, 2003		Grou	p: Not	yet kn	own
TRADEM	1 27			·			11 6	DΛT	ERIT	DOCU	MENTE		<u> </u>			
THADE		T					0.3.	FAI		DOCO	WENTS	<u>′</u> T			FIL	ING
													-	0112	DA	TE IF
EXAMINER INITIAL		DO	CUM	ENT	NUN	/IBER			D.	ATE	NAME		CLASS	SUB CLASS		PRO- IATE
	09	4	4	7	7	0	4		-	998	Roy-Chowdhur	У				
											ot ui				_	
	FOREIGN PATENT DOCUMENTS															
TRANS-																
SUB LATION																
	DOCUMENT NUMBER															
					_				╀			┼			-	
		OTH	IER C	ocu	JMEN	 NTS (Inclu	ding	 Aut	hor, Titi	 e, Date, Pertine	 nt Pa	l iges, Ei	tc.)		
,		Bleid	her,	P.A.		al., "E					CD1 on gastroir				" Scier	ıce
							he e	ffect	of p	ortacav	al shunt on dela	yed-	hypers	ensitivity	respo	nses
											:391-394 (1989					
							,				al tolerance can 81 (1997)	not ,t	e ascri	bea to b	ystand	ier
											Cells produce I					FN-
											," <u>J. Immunol. 1</u> elial and Iamina					
		cyto	toxic	ity ir	ı vitr	o and	d the	pote	ntia	l effect	s of the isolation					a!
						_		2 (19 t <i>Prot</i>			munology, Wiley	and	Sons	(1994)		
	-										cell receptor alph				by od:	
		hum	an h	epati	сТс	ells:	evid	ence	for	extrath	ymic T cell matu	ratio	n," <u>Eur</u>	. J. Imm	unol.	nt
	 	<u>26</u> :3	3114	<u>-311</u>	8 (19	96)										
											the liver," <u>Imm</u>					
								er as a 2 (20			cell apoptosis: g	avey	/ard, or	killing f	ield?,"	
		Cui,	J., e	t al.,	"Int	ibitic	n of	T He	lpe	Cell Ty	pe 2 Cell Differe					
·		Resp (199		e by	Ligar	nd-ac	tivat	ed Ve	r14	Natural	Killer T Cells,"	<u>J. Ex</u>	p. Med	. 190(6)	:783-7	′92
EXAMINER	I	1133	, , ,						DA	TE CON	ISIDERED					
*EXAMINER:	Initia	al if c	itatio	on co	nsid	ered	whe	ther	or n	ot citat	ion is in conform	ance	with f	MPEP 60)9: Dra	
		-				/									-, u	-]

Cares DTO 1440														
Form PTO-1449	U.S. D)epart	tmer	nt of	Com	merce	9		Docket No.		Seri	al No. 10	/676,0	45
(REV. 8-83) Pa	itent an	d Tra	dem	ark O	ffice	•		ENZ-	33(CIP)				•	
													٠	
OIPE tuse	ATION [several	OISCL sheet	_OSL	JRE C	CATIC	TION			•					
	Several	311000	13 11	nece.	ssai y			Applic	ants: llan, et al		<u>. </u>			
\$ 2004						٠								
JAN 2 6 2004								Filed:	Sep. 30, 2003		Grou	up: Not	vet kno	wn
TRADEMAR													,	
PRADEMA						U.S.	PATEN	T DOCU	MENTS	,				
										'			FILIN	
EXAMINER	1											SUB	DAT	
INITIAL	DO	СИМІ	ENT	NUM	IBER			ATE	NAME	c	LASS	CLASS	PRIA	
· · · · · · · · · · · · · · · · · · ·			<u> </u>	-									<u> </u>	
	1						.			1			1	
					FC	DREIG	NPAI	ENI DOC	CUMENTS	1	- 1			
·													TRAN	S-
												SUB	LATIO	
	DOG	CUME	ENT	NUM	BER		ן נ	DATE	NAME	CLA	ASS	CLASS	YES	NO
	 					· ·								
		l					İ							
	, ,			1 1					l .	1		I		
	ОТН	IER D	OCL	<u>IMEN</u>	ITS (Includ	ling Au	thor, Titl	e, Date, Pertine	ent Pa	ges, E	Etc.)		
<u> </u>	Das,	K.M.	., et	al., "	'A sh	nared	and un	ique epit	ope(s) on huma	n cold	n, sk	in and bili		-
	Das, epith	K.M. nelium	., et n det	al., " tecte	'A sh d by	nared a moi	and un	ique epit al antibo	ope(s) on huma dy," <u>Gastroent</u> e	n colo	on, sk <u>/ 98</u> :4	in and bili 64-69 (1	990)	
	Das, epith Dasg	K.M. nelium gupta	., et n det , A.,	al., " tected et al	'A sh d by l., "C	nared a moi Circula	and un noclonating im	ique epit al antibo imunoglo	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat	n cology ients v	on, sk <u>/ 98</u> :4 with u	in and bili 64-69 (1 Ilcerative	990) colitis	
	Das, epith Dasg agair 35:1	K.M. nelium gupta nst th 712-	., et n det , A., ne co 171	al., " tected et al plonic 7 (19	'A sh d by l., "C epit 94)	nared a mor Circula helial	and un noclona iting im proteir	ique epit al antibod imunoglo i detecte	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat d by a novel m	in cology rology ients v onoclo	on, sk <u>/ 98</u> :4 with u onal a	in and bili 64-69 (1 Ilcerative ntibody,"	990) colitis <u>Gut</u>	
	Das, epith Dasg agair 35:1	K.M. nelium gupta nst th 712- erty,	., et n det , A., ne co 171 D.G.	al., " tected et al plonic 7 (19 , et a	'A sh d by l., "C epit 94)	nared a mor Circula helial	and un noclonal iting im protein ct cyto	ique epit al antibod imunoglo i detecte toxic lyn	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat d by a novel m nphocytes subs	in cology ients v onoclo	on, sk <u>/ 98</u> :4 with u onal a	in and bili 64-69 (1 Ilcerative ntibody,"	990) colitis <u>Gut</u>	er in
	Das, epith Dasg again 35:1 Dohe imm	K.M. nelium gupta nst th 712- erty, l une h	., et n det , A., ne co 171 D.G. nome	al., " tected et al plonic 7 (19 , et a	'A sh d by l., "C epit (94) al., "I sis,"	nared a mor Circula Chelial Distinc J. He	and un noclonal iting im proteir ct cyto patolog	ique epit al antibod munoglo n detecte toxic lyn ay 28:59	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat d by a novel m nphocytes subs (1998)	in colo rology ients v onoclo ets su	on, sk / 98:4 with u onal a	in and bili 64-69 (1 Ilcerative ntibody," a role for	990) colitis <u>Gut</u> r the liv	er in
	Das, epith Dasg again 35:1 Dohe imm	K.M. nelium gupta nst th 712- erty, l une h	., et n det , A., ne co 171 D.G. nome	al., " tected et al blonic 7 (19 , et a costas , et a	'A sh d by l., "C epit (94) al., "I sis,"	nared a more control of the lial of the lial of the lial of the lial of the lian of the li	and un noclonating im protein ct cyto patolog an lymp	ique epit al antibod munoglo n detecte toxic lyn py 28:59 phocytes	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat d by a novel m nphocytes subs (1998) with dual T ce	in color erology ients v onoclo ets su	on, sk 98:4 with use onal as ggest	in and bili 64-69 (1 Ilcerative ntibody," a role for	990) colitis <u>Gut</u> r the liv	er in
	Das, epith Dasg again 35:1 Dohe immediate pher	K.M. pupta nst th 712- erty, une h erty, notype	., et n det , A., ne co 171 D.G. nome D.G. e and	al., " tected et al plonic 7 (19 , et al eostas , et al d fun a, M.,	'A shid by l., "C epit 94) al., "I sis," ction	nared a more a m	and un noclonal iting im protein ct cyto patologian lymp de norm	ique epit al antibod imunoglo n detecte toxic lyn gy 28:59 bhocytes nal adult	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat d by a novel m nphocytes subs (1998)	in cold erology ients onocid ets su ets su Il and egy 26	on, sk y 98:4 with use onal as ggest natura :445	in and bili 64-69 (1 licerative ntibody," a role for al killer ce A (1997)	990) colitis Gut the liv	
	Das, epith Dasg again 35:1 Dohe immed pher Garc lymp	K.M. nelium gupta nst th 712- erty, une h erty, notype iia-Ba phocy	., et n det , A., ne co 171 D.G. nome D.G. e and rcina	al., " tected et al plonic 7 (19 , et al eostas , et al d fun a, M., " Imm	'A shid by l., "C epit 194) al., "I sis," ction, et anuno	nared a more a m	and un noclonal iting im proteir ct cyto patolog an lymple e norm etectic 95-98	ique epit al antibod munoglo detecte toxic lyn gy 28:59 bhocytes al adult n of cell (1994)	ope(s) on huma dy," <u>Gastroente</u> bulin G1 in pat d by a novel m nphocytes subs (1998) with dual T ce liver," <u>Hepatolo</u> -adhesion mole	ets su Il and agy 26 cules	on, sk v 98:4 with up ponal argest ggest natura :4454 on hur	in and bili 64-69 (1 licerative ntibody," a role for al killer ce A (1997) man liver-	990) colitis Gut r the liv	ated
	Das, epith Dasg again 35:1 Dohe immore Gard lymp	K.M. nelium gupta nst th 712- erty, l une h erty, l notypo iia-Ba phocy cock,	., et n det , A., ne co 171 D.G. nome D.G. e and rcina rtes,"	al., " tected et al olonic 7 (19 , et a costas , et a d fun a, M., " Imm et al	'A shid by I., "Content of the series of the	nared a more a m	and un noclonal iting im proteir ct cyto patolog an lymple norm retection 95-98 ession co	ique epit al antibod munoglo detecte toxic lyn gy 28:59 bhocytes al adult n of cell (1994) of Insulit	ope(s) on humady," Gastroente bulin G1 in pat d by a novel m hphocytes subs (1998) with dual T ce liver," Hepatolo -adhesion molecis is in Non-Obese	ets su Il and agy 26 cules a	on, sk v 98:4 with up onal and ggest natura :445 on human	in and bili 64-69 (1 licerative ntibody," a role for al killer ce A (1997) man liver-	990) colitis Gut r the live	ated
	Das, epith Dasg again 35:1 Dohe immediate phen Gard lymp Hand Insul	K.M. gupta nst th 712- erty, l une h erty, l notype ia-Ba phocy cock, lin Ad	., et n det , A., ne co 171 D.G. nome D.G. e and rcina rtes,'	al., " tected et al olonic 7 (19 , et a sostas , et a d fun a, M., " Imm et al istrati	'A sh'd by l., "C epit 194) al., "I sis," al., "ction, et a nuno sion ls	nared a more a more a more delial bisting J. He 'Human in the al., "DI. 82:5 suppress Asso	and un noclonal iting im protein ct cyto patolog an lymple norm letection 95-98 ssion cociated	ique epit al antibod munoglo detecte toxic lyn ay 28:59 phocytes hal adult on of cell (1994) of Insulit with Se	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in Non-Obese lective Express	ets sull and egy 26 cules of Diab	on, sk v 98:4 with upnal an ggest natura :445/ on hum etic (N Interle	in and bili 64-69 (1 licerative ntibody," a role for al killer ce A (1997) man liver- NOD) Mice eukin-4 ar	990) colitis Gut r the live ell associate by Ornd -10,	ated
	Das, epith Dasg again 35:1 Dohe immi Dohe pher Gard Iymp Hand Insul Tran (199	K.M. gupta nst th 712- erty, une h erty, notypo ia-Ba phocy cock, lin Ad sform	., et n det n, A., ne co 1711 D.G. nome D.G. e and rcina rtes,' W., dmini	al., " tected et al blonic 7 (19 , et a costas d fun a, M., " Imm et al istrati	'A shd by I., "C epit 94) Al., "I sis," ction , et a nuno vth F	nared a more a more a more description of the last a more and a mo	and un noclonal iting im protein ct cyto patolog an lymphe norm etectio 95-98 ession cociated b, and	ique epit al antibod imunoglo detecte toxic lyn ay 28:59 phocytes al adult on of cell (1994) of Insulilt with Se Prostagl	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in pat	in cold prology ients vonocide ets su Il and igy 26 cules of the Diab ion of J. Path	on, sk y 98:4 with use on a large ggest natura :445/ on human etic (Natural)	in and biline and biline and biline and biline arole for all killer can be a (1997) and liver-NOD) Micropole and biline arole arole for an arole for arole for an arole for arole for a	990) colitis Gut r the live ell essociate by Or nd -10, -1197	ated
	Das, epith Dasg agair 35:1 Dohe immorpher Garc lymp Hand Insul Tran (199 Hash	K.M. nelium gupta nst th 712- erty, l une h erty, l notype ia-Ba bhocy cock, lin Ad sform 05)	n, et n det n, A., ne co 171 D.G. nome D.G. e and rcina rtes,' W., dmini ning	al., " tected et al plonic 7 (19 , et a costas , et a d fun a, M., " Imm et al istrati Grow	'A shd by I., "C epit 194) al., "I sis," ction et a nuno vth F al.,	Distinct J. He "Human in thal., "DI. 82:5 actor-"Cyto"	and un noclonal ting improteir ct cyto patolog an lympe norm retection 95-98 ession cociated toxic N	toxic lyngy 28:59 phocytes all adult on of cell (1994) of Insulikt with Sepressage K1.1 Ag	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in Non-Obese of bulin G1 in Non-Obes	in cold prology ients vonocide ets su Il and egy 26 cules of e Diab ion of J. Path	y 98:4 with upnal and ggest natura:445/con hum etic (Natural) Interfer. 147	in and biline in and biline in and biline in increase in increase in an increase in increa	990) colitis Gut r the live ell essociate by Or nd -10, -1197	ated
	Das, epith Dasg again 35:1 Dohe immediate phen Gard Iymp Hand Insul Tran (199 Hash indus	K.M. nelium gupta nst th 712- erty, l erty, l erty, l otype ia-Ba bhocy cock, lin Ad sform 05) nimote ced ir	n det n det n A., ne co 171 D.G. nome D.G. e and rcina rtes," W., dmini ning	al., " tected et al olonic 7 (19 , et a costas , et a d fun a, M., " Imm et al istrati Grow /., et	'A shid by l., "C epit 94) al., "I sis," ction , et a nuno , "S ion Is vth F	nared a more a more a more delial bisting J. He 'Human in the al., "DI. 82:5 actor-conice bisting by the arms of t	and un noclonal iting im proteir ct cyto patolog an lymple e norm letectic 95-98 ession cociated by IL-12	ique epit al antibod munoglo detecte toxic lyn ay 28:59 phocytes hal adult on of cell (1994) of Insulilt with Se Prostagl (K1.1 Ag 2," J. Im	ope(s) on humady," Gastroented by Gastroented bulin G1 in pate of the bulin G1 in pate of	ets sull and egy 26 cules of J. Path	y 98:4 with upnal argest ggest natura:445/con hur etic (Natural) Interfer. 147 with it	in and biline and biline and biline and biline at the ntibody," a role for all killer celes (1997) man livered (1997)	990) colitis Gut r the live ell eassocia e by Or nd -10, -1197	ated al
	Das, epith Dasg again 35:1 Dohe immediate pher Gard Iymp Hand (199 Hash induced Haya	K.M. nelium gupta nst th 712- erty, l une h erty, l notype ia-Ba phocy cock, lin Ad sform 05) nimote ced ir akawa	n det n det n A., ne co 171 D.G. nome D.G. e and rcina rtes,' W., dmini ning n the a, T.	al., " tected et al plonic 7 (19 , et a postas , et a d fun a, M., " Imm et al istrati Grow /., et e liver , et a	A shid by I., "C epit 94) II., "I sis," ction , et a nuno yth F al., " of r	Distinct J. He 'Human in the lal., "DI. 82:5 actor-	and un noclonal ting im proteir ct cyto patolog an lymple norm letectio 95-98 ession cociated β, and toxic Noy IL-12 e thym	ique epit al antibod munoglo n detecte toxic lyn ay 28:59 phocytes nal adult on of cell (1994) of Insulilt with Se Prostagl K1.1 Ag 2," J. Imi	ope(s) on humady," Gastroented by Gastroented bulin G1 in pate of	ets sull and egy 26 cules of J. Path	y 98:4 with upnal and ggest natura:445/con human	in and biline and biline and biline and biline arole for a role for al killer central killer cen	990) colitis Gut r the live ell eassocia e by Ornd -10, -1197 ate TCF	ated al
	Das, epith Dasg again 35:1 Dohe immi Dohe pher Gard Iymp Hand Insul Tran (199 Hash indus diver Med	K.M. pelium gupta nst th 712- erty, une h erty, hotype cock, lin Ad sform 05) nimote ced ir akawa rse cy . 176	n, et n det	al., " tected et al plonic 7 (19 , et a costas , et a d fun a, M., " Imm et al istrati Grow /., et e liver , et a p-274	'A shd by I., "C epit 194) II., "I sis," ction , et a nuno ., "S ion Is yth F al., "I and o I (19	nared a more a more a more description of the sector- "Cyto" mice be Muring overex (192)	and un noclonal iting im protein ct cyto patolog an lymphe norm etectio 95-98 ession cociated β, and toxic Noy IL-12 e thym cpresse	ique epit al antibod imunoglo in detecte toxic lyn ay 28:59 bhocytes al adult in of cell (1994) of Insulilt with Se Prostagl K1.1 Ag 2," J. Imi ic CD4 + s the V I	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in pat	in cold prology ients vonocide ets sur li and ets sur li and ets cules ets ets cules ets ets ets ets ets ets ets ets ets e	on, sk y 98:4 with use on a large of the second of the s	in and biline and biline and biline and biline arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole (1995) and biline arole (1995) Thyo) that family,"	990) colitis Gut r the live associate by Or -1197 ate TCF t secret J. Exp.	ated al
	Das, epith Dasg agair 35:1 Dohe immorpher Garc lymp Hand Insul Tran (199 Hash induction Haya diver Med Hibi,	K.M. nelium gupta nst th 712- erty, l erty, l erty, l erty, l erty, l hotype cock, lin Ad esform 05) nimote ced ir akawa rse cy . 176 S., e	n, et n det	et al plonic 7 (19 , et al postas , et al de fun et al istrati Grow 7 , et al person et al perso	'A shd by l., "C epit 194) al., "I sis," ction et a nuno vth F al., "I and o l (19 rcula	Distinction of the second of t	and un noclonal iting im protein ct cyto patolog an lymple norm retection 95-98 ression cociated -B, and toxic Noy IL-12 e thym cpresse	toxic lyngy 28:59 phocytes all adult with Se Prostagl K1.1 Ag 2." J. Imic CD4 + s the V to the sto th	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in pat	in cold prology ients vonocide ets sur li and ets sur li and ets cules ets ets cules ets ets ets ets ets ets ets ets ets e	on, sk y 98:4 with use on a large of the second of the s	in and biline and biline and biline and biline arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole (1995) and biline arole (1995) Thyo) that family,"	990) colitis Gut r the live associate by Or -1197 ate TCF t secret J. Exp.	ated al
EV A MAINIED	Das, epith Dasg agair 35:1 Dohe immorpher Garc lymp Hand Insul Tran (199 Hash induction Haya diver Med Hibi,	K.M. nelium gupta nst th 712- erty, l erty, l erty, l erty, l erty, l hotype cock, lin Ad esform 05) nimote ced ir akawa rse cy . 176 S., e	n, et n det	et al plonic 7 (19 , et al postas , et al de fun et al istrati Grow 7 , et al person et al perso	'A shd by l., "C epit 194) al., "I sis," ction et a nuno vth F al., "I and o l (19 rcula	Distinction of the second of t	and un noclonal ting improteir ct cyto patologan lymple norm letectic 95-98 ession cociated by IL-12 e thymple the cyto characteristics and toxic Noy IL-12 e thymple cytose ntibodi Immun	ique epit al antibod munoglo n detecte toxic lyn ay 28:59 phocytes hal adult on of cell (1994) of Insulilt with Se Prostagl IK1.1 Ag 2," J. Im ic CD4 + s the V the es to the ol. 54:10	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in pat	in cold prology ients vonocide ets sur li and ets sur li and ets cules ets ets cules ets ets ets ets ets ets ets ets ets e	on, sk y 98:4 with use on a large of the second of the s	in and biline and biline and biline and biline arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole (1995) and biline arole (1995) Thyo) that family,"	990) colitis Gut r the live associate by Or -1197 ate TCF t secret J. Exp.	ated al
EXAMINER	Das, epith Dasg agair 35:1 Dohe immorpher Garc lymp Hand Insul Tran (199 Hash induction Haya diver Med Hibi,	K.M. nelium gupta nst th 712- erty, l erty, l erty, l erty, l erty, l hotype cock, lin Ad esform 05) nimote ced ir akawa rse cy . 176 S., e	n, et n det	et al plonic 7 (19 , et al postas , et al de fun et al istrati Grow 7 , et al person et al perso	'A shd by l., "C epit 194) al., "I sis," ction et a nuno vth F al., "I and o l (19 rcula	Distinction of the second of t	and un noclonal ting improteir ct cyto patologan lymple norm letectic 95-98 ession cociated by IL-12 e thymple the cyto characteristics and toxic Noy IL-12 e thymple cytose ntibodi Immun	ique epit al antibod munoglo n detecte toxic lyn ay 28:59 phocytes hal adult on of cell (1994) of Insulilt with Se Prostagl IK1.1 Ag 2," J. Im ic CD4 + s the V the es to the ol. 54:10	ope(s) on humady," Gastroented bulin G1 in pate of bulin G1 in pat	in cold prology ients vonocide ets sur li and ets sur li and ets cules ets ets cules ets ets ets ets ets ets ets ets ets e	on, sk y 98:4 with use on a large of the second of the s	in and biline and biline and biline and biline arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole for all killer cells (1997) and liver-NOD) Micropoleukin-4 arole (1995) and biline arole (1995) Thyo) that family,"	990) colitis Gut r the live associate by Or -1197 ate TCF t secret J. Exp.	ated ral

`						_							Sheet	<u>4</u> o	f 13	
Form PTO-14	149 L	J.S. [)epar	tmer	nt of	Com	merc	e			Docket No.		Seria	al No. 10	/676,0	45
(REV. 8-83)	Pate	nt an	d Tra	adem	ark (Office	9			ENZ-6	63(CIP)					
INFO	2010 T	1001	DISC	1 001	וחר (CIT A	TION									
INFOF	se se															
/0. 4	(C)						, ,			Applic	ants: llan, et al					
/	nna 🛬)							-							
JAN 2 6 21	Σ.)					•	* .		Filed:	Sep. 30, 2003		Grou	in: Not	yet kno	214/0
FEE	of C.	•								,,,,,,	- Cop. Co, 2000		0,00	ip. Not	, .	70011
BTRADE	MA						U.S.	PAT	ENI	DOCU	MENTS	<u>,</u>	<u> </u>			
-											,			T .	FILIN	vG
57444455															DAT	
EXAMINER INITIAL		00	CUM	IENIT	AII IA	ADED			_	ATE	NIANAE		CLASS	SUB	APP	
IIIIIAL		100	T		T	T	Ή-	T	D,	415	NAME			1	PRIA	
		 	<u> </u>	<u> </u>	ļ		<u> </u>	<u> </u>	· .							
				İ				1						,		
		<u> </u>	·	' 		FC	ÖREI	ĠN PA	ATE	NT DOC	UMENTS	•		•	'	
															TRAN	
		DO	сим	ENT	NUM	IBER			٦	ATE	NAME			SUB CLASS	LATIO YES	ΝΟ <u>ΣΙΙ</u>
									-		100	(1.	ASS	OLAGO	120	140
										· · ·						
							-		\vdash			-				<u> </u>
		OTH	 IER C	OOCL	JMEN	 its ((Inclu	 ding	 Aut	hor, Titl	 e, Date, Pertine	 ent Pa	ges, E	tc.)	ļ	
		llan,	Y., €	et al.	, "Tr	eatm	ent d	of exp	erir	mental c	olitis through in	ducti			ance	
											14:260 (1998)					
										1997)	SL and BCL-2 in	n nor	mai nu	man iiver	aerive	a
											Role of NK1+	T Ce	lls in IL	-12-Indu	ced	
		lmm	une f	Resp	onse	s In \	Vivo,	" <u>J. l</u>	<u>mm</u>	unol. 16	<u>80</u> :16-19 (1998)			• •	
											KT) Cell Ligand					
											by Inducing Into on NKT Cells,					
		(199	99)												•	,
											sed cells secret	ing a	ntibod	y of pred	efined	
					_			5-497			- 4- 1			1141 # =	<u>,,</u>	
			n, K., (199		II., I	nteri	eukin	I- I U-C	etic	cient mi	ce develop chro	nic ei	nteroco	outis," <u>Ce</u>	<u>: /5</u> :2	ნ3-
-					es, N	И.С.,	et a	I., "IL	4-	producir	ng NK T cells are	e bias	sed tov	vards IFN	l-gamm	na l
		prod	luctio	n by	IL-1	2. In	fluen	ce of	the	microe	nvironment on					
										515 (1						
]	Ma,	X., e	it al.,	, "[h le "	e inte	erleu!	kin 13	2 p4	10 gene	promoter is prii 7 (1996)	med t	by inte	rferon ga	mma ir	۱
-											ll differentiation)ner	eration	n of CD3		
		CD4	+/CI	D8+	TCR	oeta-	cells	and	CD	3-4-8-T	CRbeta + cells f	rom (CD4-8-	TCRbeta	-athym	ic
-		nude	e bon	ie ma	irrow	cell	s by	cultui	re w	vith pare	enchymal liver c	ells,"	J. Leu	kocyte B	iology	,
EXAMINER	L!	<u>63</u> :5	75-5	83 (1998	3)		T	D.4	TE 001	CIDEDED		1			
CVWINIIIAEK								ļ	υA	IE CON	ISIDERED		•			1
*EYAMINED.	Initia	ol if a	itatia		noid:	2500	sada -	* l= = -		::			***	MOED CO		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

							_							Snee		<u> 13</u>	
Form PTO-14	149 L	J.S. [Depai	rtmer	nt of	Com	merc	e		Atty. [ENZ-6		cket No.		Seri	al No. 10)/676,0	45
(REV. 8-83)	Pate	nt an	d Tra	adem	ark (Office	•			1112-0		(Cii)					
INFO	20 4 A T	10N 1	2100		וחב י	~1 ~ ^ :	T101										
INFOF	rivia i Se se							i		1					·		•
OIPE	40						, ,			Applic	an	nts: Ilan, et al		L			
/	\$																
JAN 2 6 201	(بع 34	•								Filed:	S	ep. 30, 2003		Grou	up: Not	yet kn	own
漫。											_	-p:,			-,	,	
TO THADEN	8						U.S.	PAT	ENT	DOCU	MI	ENTS ,					
												· · · · · · · · · · · · · · · · · · ·				FILI	
EXAMINER															SUB		re if Pro-
INITIAL		Od	CUM	IENT	NUN	1BER			D.	ATE	۱	VAME	C	LASS	CLASS	PRIA	
													1.				
	.	 		ļ				 	 	 	H		+	- :	 	+	
'		ļ		ļ	l ·		DEN	CALD		NT DOC		BATRITO				1	
· · · · · · · · · · · · · · · · · · ·							JKEN	JIN PA	T	NT DOC	0,	IVIENTS		· I	· · · · · ·	l	
		TRANS-														IS-	
		50	~ 4												SUB		
		וטטו	CUM	ENT	NUIV	IBER			٥	ATE		NAME	CLA	ASS	CLASS	YES	NO
							<u> </u>		\vdash		+						Τ
									 		4						
	1	OTH	IER D	OCL	JMEN	ITS (Inclu	ding	Aut	thor, Titl	le,	Date, Pertinen	t Pa	ges, E	tc.)		
•												oha/beta+ cells 33-638 (1995)		w ciu	es to the	ır orıgır	١,
												cytokine-induce		srupti	ion of T8	4 barrie	er
												enterology 113					
•		Mart	th, I. raliza	., et a	al., " of II	High	dose	e oral	tok	erance ir E-beta si	n (ovalbumin TCR cretion and T ce	tran	sgeni	c mice: s	systemi	С
	i.	157	:234	8-23	57 (1	996) }			. Dota 3			n ap	optos	515, <u>J. II</u>	HITIUTIOI	<u>.</u>
		Mata	ziņge	r, P.,				lange	r, a	nd the e	xt	tended family,"	Anr	ı. Rev	. Immun	ol. 12:9	99:1-
			5 (19			- l "	Cuto	ا ماداد	· b	-1		1 1 1			· -		
,												d autoantibody isease," <u>J. Exp</u>					
		Murc	ch, S	.H.,	et al	, "Lo	catio	on of	tun	nour nec	ro	sis factor alpha	by	immu	<u>o.o-7-0.</u> inohistoc	hemisti	ry in
		chro	nic i	nflam	mate	ory b	owel	dise	ase,	," Gut 3	<u>4</u> :	1705 (1998)					
,												liver allografts	by ir	ntrapo	rtal injec	tion of	
												376 (1992) n 12 abrogate (etal	hliche	d experin	nental	
		colit	is in	mice	," <u>J.</u>	Exp.	Med	1. 18:	<u>2:12</u>	281-129	0	(1995)				neritai	
		Neur	rath,	М.,	et al.	, "Ex	perir	nenta	ıl gr	ranuloma	ato	ous colitis in mi					
		by ir	nduct	tion o	of TG	F-be	ta-m	ediate	ed c	oral toler	ar	nce," <u>J. Exp. M</u>	ed.	<u>183</u> :2	605-261	6 (199	6)
		cells	e, r. in th	, eເຂ neth	ıı., I vmic	atro	phv (of mi	oo e s	ur aonor Sufferina	r C i fr	ytotoxic T lymprom acute graft	-ver	ytes a	ana nost ost disea	NKT.T se."	+
		<u>lmm</u>	unol	ogy S	<u>5</u> :24	18-25	6 (1	998)			_ ''						
EXAMINER									DA	TE CON	IS	IDERED					,
*EXAMINER:	Initia	al if c	itatio	on co	nside	ered,	whe	ther	or n	ot citati	ior	n is in conforma	nce	with	MPEP 60	9; Dra	w
line through o	citatio	n if r	ot in	con	form	ance	and	not c	ons	sidered.	Ir	nclude copy of	this	form	with nex	t	
communication	on to	annli	cant														

													Shee	t <u>6</u> c	of 13	
Form PTO-14	49 U	I.S. [Depai	rtmer	nt of	Com	merc	е			ocket No.		Seri	al No. 10	/676,04	1 5
(REV. 8-83)	Pater	ntan	nd Tra	adem	ark (Office	3			ENZ-6	3(CIP)				•	
(1.12 V., 0 00)	1 410.	ii ui		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	uik (311100	•						f			
INFOF														•		
OIPE	se se	/eral	shee	ts if	nece	ssary	y)	٠.								
	2									Applica	ints: Ilan, et	al				
JAN 2 6 200	(بر ۱۷	•			•							_				
E										Filed:	Sep. 30, 20	03	Grou	up: Not	yet kno	wn .
TRADEM	ON /				<u> </u>		11 \$	ΡΔΤ	FNIT	DOCUM	/FNTS					
, ADD			·				0.3.	101	1	BOCON	ILIA 1 3	7		1	FILIN	IG.
·														ŀ	DAT	
EXAMINER		l											CLASS	SUB	APPF	
INITIAL		DO	CUM	IENT	NUN	/IBER	1		D/	ATE	NAME		CLASS	CLASS	PRIA	.TE
	•															
													-			
'	FOREIGN PATENT DOCUMENTS															
														TRANS		
		חח	CUM	FNT	NIL IN/	IRER				ATE	NAME			SUB CLASS	LATIO YES	<u>N</u> NO
			COIVI		14014	IDEI			"	A12	IVAIVIL	'	CLASS	CLASS	163	NO
'											, Date, Pert					
											edominance				ession i	in
		Pode	gut o	t pat	ients	al al	1 Cro	nn's	dise	ease," Al	n. J. Pathol. disease," <u>Ne</u>	150:8	823-832	2 (1997) d 225:01	20 025	
		(199	91)	, D.N	, G t	aı.,	IIIIIa	пппа	tory	Dowei	iisease, <u>ive</u>	w Eng	ı. J. Me	<u>u. 325</u> .9.	20-930	
		Pou	wels,	P.H.	, et	al., C	Clonin	g Ve	ctoi	rs, A Lab	oratory Man	ual, E	lsevier,	New York	(1985)
		Pow	rie, F	., et	al.,	"Inhil	bition	of T	h1	response	s prevents i	nflamr	natory b	owel dise	ease in	scid
											cells," <u>Immu</u>					
		Qin,	S., 6	et al.	, "'In	itecti	ous'	Trans	spla	ntation 1	olerance," §	Scienc	<u>e 259</u> :9	74-977 (1993)	
											pheral T cell					
											" Clin. Exp.					
·							Vect n, Bo				Molecular C	loning	Vectors	s and thei	r Uses,	
											ease in mice	with:	a disrun	ted interle	ukin-2	
							1 (19			0 013			_ u.u.up		-unii 2	
	T	San	der,	J.H.,	et al	., "N	lultip	le do:			enous interl					
EXAMINER		Crof	nn's c	disea	se. C	rohn	's Di	sease			ıp," <u>Gastroe</u>	nterolo	ogy 113	:383-89	(1997)	
											SIDERED					
*EXAMINER:																v
line through o communication					torm	ance	and	not c	ons	idered.	Include copy	of th	is form	with next		

												Stieet		<u> </u>	
Form PTO-144		·					e			Docket No. 33(CIP)		Seria	al No. 10	/676,045	,
(REV. 8-83) P	atent an	d Tra	adem	ark (Office	•									
1	IATION I											i			
OIPE	several	snee	ts II	nece	ssary	/)		,	Applic	ants: Ilan, et al		<u> </u>			
														•	
JAN 2 6 2004	1								Filed:	Sep. 30, 2003		Grou	ıp: Not	yet know	/n
	<u> </u>													·	
& TRADEMART	<u> </u>					U.S.	PAT	EN	r Docui	MENTS /	<u>,</u>			FILING	
														DATE	
EXAMINER INITIAL	DO	CLIM	IENIT	NII IN	1BER			٦,	ATE	NAME		CLASS	SUB	APPRO	
MITTAL	- 50				IBLA	<u> </u>	Γ	۲	AIC	NAME	+			PRIAT	<u> </u>
		ļ 	<u> </u>		 		<u> </u>	_					 	7.	
ł ł		۱ .	1 .			 	ON D	 Tr	NT DOG	NAMENTO					
<u> </u>					FC	JKEI	JN PA	A I E	NI DUC	CUMENTS					
							TRANS-								
	DOG	сим	FNT	NUM	IRFR			D	ATE	NAME			SUB CLASS	LATION YES I	NO
								L		TVAIVIE	CL	ASS	CLASS	120	
· · · · · · · · · · · · · · · · · · ·										e, Date, Pertiner					
·									ymphok 994)	ine-Producing Ph	enot	type b	y CD4 +	T Cells,"	
	Sede	er, R.	Α., ε	et al.	, "Int	erleu	kin 1	2 A	cts Dire	ctly on CD4 + T	Cell	s to E	nhance P	riming for	r
	Inter	rferor	n) Pi	oduc	tion	and I	Dimin	ish	es Interl 1993)	eukin 4 Inhibitior	n of	Such f	Priming,"	Proc. Na	<u>tl.</u>
										expanded in auto	imm	une lp	r mice ai	re probabl	ly
								_		J. Immunol. 147					
	II									ia are Necessary tivation in Interle			•		
	Infed	ction	and	Imm	unity	<u>66</u> :5	224-	52	31 (199	8)			_		
										and TGF-beta res				е	-
										Mosby, St. Louis				995)	
	Taka	ahash	ni, F.	, et a	ıl., "l:	solat	ion a	nd (characte	rization of a colo	nic	autoar	ntigen sp	ecifically	
	reco	gnize	ed by	colo	n tis	sue-t	ound			obulin G from idi					
					1-31 al., "			es	NK1.1 +	alpha beta T ce	lls w	ith no	tent cyto	toxicity is	
	the I (199	iver ()6)	of mi	ice vi	a pro	duct	ion o	f IL	-12 fron	n Kupffer cells,"	<u>J. In</u>	nmunc	ol. 156:2	436-2442	2 -
		mo, l :219				l tole	rance	in e	experim	ental animals," <u>I</u>	nt. A	Arch. A	Allergy In	nmunol.	
EXAMINER								DA	TE CON	ISIDERED					
										on is in conform					
line through cit	ation if r	not in	con	form	ance	and	not c	ons	sidered.	Include copy of	this	form	with next	t	
communication	to appli	cant.													- 1

														Sneet	8(or <u>13</u>	•
Form PTO-14	49 U	I.S. D)epar	tmer	nt of	Com	merc	e	-	,	Docket No. 33(CIP)			Seria	l No. 10	/676,0	45
(REV. 8-83)	Pater	nt and	d Tra	dem	ark (Office	•										
O I P (a)																	
	5					•				Applic	ants: Ilan, e	et al	1				
JAN 2 6 2004	*																
2 2004	<i>((((((((((</i>										Sep. 30, 2	003		Grou	p: Not	yet kno	own
RADEMAN							U.S.	PAT	ENT	DOCU	MENTS						
																FILI	NG ſE IF
EXAMINER													_,	.ASS	SUB CLASS	APP	RO-
INITIAL		000	CUM	ENI	NUN	1BER	<u> </u>	Τ_	D,	ATE	NAME		+-		CEASS	PRIA	ATE
							ļ				<u> </u>		-				*
						 	 BEI	SN PA) ATF	NT DOG	UMENTS						
								314 1 /	Ϊ	111 000	JOINLINIS	ľ					
										•				1			
	DOCUMENT NUMBER DATE NAME CLASS CLASS VES NO																
													•				
															÷		
· '	·										le, Date, Pe						·
											tes Express del," <u>Hepat</u>						al
		Vica	ri, A.	Р., е	t al.,						a new fam						ay
		_		(199		et :	" · اد	Oral J	neu	lin Trea	tment Supp		Vir	us-ind	uced An	tigen	
<u>.</u>		spec	ific [Destr	uctio	n of	βСе	lls an	d P		Autoimmur						″ <u>J.</u>
								(1996				**	: ala		-11	-1-110 #	
		Nucl	. Me	d. 24	<u>1</u> :316	6-325	5 (19	83)			mor localiza						
		Weir	ner, F	1., et	al.,	"Ora	I Tol	eranc			ogic Mecha						
										Disease 994)	s by Oral A	aminis.	trati	on of	Autoant	igens,"	
											atl. Acad. S	Sci. US	A 9	<u>1</u> :107	62-1076	55 (199	94)
											e mechanisı	ns and	tre	atmer	nt of auto	oimmur	ne
	.	disea	ses,	<u>" lmı</u>	munc	ol. To	day	<u>18:3</u> :	35-3	343 (19	97)						
											of oral tole (1993)	rization	wit	:h my	elin antig	jens in	
		Yosh	nimot	o, T	., et	al., "	CD4	pos, i	NK1	.1pos T	cells prom						
EXAMINER		respo	onse	to ir	vivo	cha	lleng	e wit			," J. Exp. N	led. 17	<u>'9:1</u>	285-1	295 (19	94)	
								.			ISIDERED						
*EXAMINER: line through c																	w
communication						a. 100	anu		.0113		inicidate co	ργ Οι ί	1113		WIGH HEX	•	

•										· · · · · · · · · · · · · · · · · · ·	······································		Sheet			_
Form PTO-14	49 L	J.S. [Depai	rtmer	nt of	Com	merc	е			Docket No. 33(CIP)		Seria	al No. 10	/676,0	45
(REV. 8-83)	Pate	nt an	d Tra	adem	ark C	Office	•			E1V2-0)3(CIF)					•
	MAT se se															
	.c.	٠ ١								Applic	ants: llan, et a	ıl	1			
JAN 2 6 21	004															
PARTE	A PRINCE	/						,	*	Filed:	Sep. 30, 200	3	Grou	ıp: Not	yet kn	own
TRADE	<u> </u>						U.S.	PAT	ENT	L DOCU	MENTS	· ;				
EXAMINER														SUB		NG FE IF PRO-
INITIAL		DO	CUM	IENT	NUN	1BER			D,	ATE	NAME	C	LASS	CLASS	PRI	
		,														
	- 	1	I	 		FC	REIC	N PA	ATE	NT DOC	UMENTS	t .		I	۱. 	
:		DO	CLIM.	ENT	NUM	BED		-	5	ATE	NAME			SUB	TRAN LATIO	<u>NC</u>
			COIVI	CIN I	14014	DEN	ı		L	A1E	IVAIVIE	CLA	ASS	CLASS	YES	NO
													ļ			
											e, Date, Pertin					
										1 + T Ce 7 (1995	ells in a TH2 R	espons	e and	in Immu	noglob	ulin E
		Yu,	S.Y.,	et a	l., "F	ortal	vein	adm	inis	tration o	of donor cells purgery 116:22				llospec	ific
		Buro	lin, N	l., et	al., '	"lmm	uniza	tion	wit	h alpha-	galactosylcera J. Immunol. 29	mide p	olarize	es CD1-re	eactive	NKT
		Gots	man	, l., e	et al.	, "Eff	fect o	of per	riph	eral imn	nune tolerance				mphod	ytes
											9-750 (2000) experimental co	olitie: th	ne role	of NK1	1 liver	
			phocy								ander effect,"					
		Sred	lni, B								ponse in tumo		_		ncer	
											er Inst. 88:12 ," New Englan				1221	1231
		(200)2)													
											: clinical chara 9 (1999)	cteriza	tion a	nd risk fa	actors 1	or
			ndra,								in obesity," <u>Ac</u>	ta Pae	diatr.	Scand. 6	<u>9</u> :25-3	0
		Coh	en, B	3., et	al., '	'Mod	ulatio	on of	Ins	ulin Act	ivities by Lept	in," <u>Sci</u>	ence	<u>274</u> :118	5 (199	6)
EXAMINER	· !			_					DΑ	TE CON	ISIDERED					
											on is in confor					w
line through of communication					torm	ance	and	not c	ons	sidered.	Include copy	of this	form	with nex	t	

													sneet	<u> 10</u> c	it <u>13</u>	
Form PTO-14	149 L	J.S. E	Depai	tmer	nt of	Com	merc	e			Docket No. 63(CIP)		Seri	al No. 10	/676,0	45
(REV. 8-83)	Pate	nt an	d Tra	adem	ark C	Office	;	•	•		, , ,					
INFO	RMAT	ION I	DISC	LOSI	JRE (CITA	TION									
	ze sev												<u> </u>			
0,,,	- 'C)	\								Applic	ants: llan, et a	al				
	2004	~														
JAN 2 6	, c									Filed:	Sep. 30, 200	3	Gro	up: Not	yet kno	own
CAT & TRAI	EMAR			-			U.S.	PAT	ENT	DOCU	MENTS		<u> </u>			
	1											<i>'</i>			FILI	
EXAMINER														SUB	APP	re if rro-
INITIAL		DO	СПМ	ENT	NUN	1BER			D,	ATE	NAME	(CLASS	CLASS	PRI/	
									ĺ							
														· · · · · · · · · · · · · · · · · · ·		
	l	FOREIGN PATENT DOCUMENTS														
TRANS-																
DOCUMENT NUMBER																
		DO	сим	ENT	NUM	IBER				ATE	NAME	CL	ASS	SUB CLASS	YES	NO
								_	<u> </u>							
	,															
	· · · ·										e, Date, Perti					
											ATP homeosta 659-1664 (19		humar	n nonalcol	nolic	
											and Steatoher		V. Noi	nalcoholic	fatty l	liver
		dise	ase a	bnor	malit	ieș ir	n ma	croph			n and cytokin					
,	\vdash			_		<u>G1-G</u>			ient	(ah/ah)	mice are prot	ected :	from T	call mad	iatad	
,		hepa	atoto	xicity	/: Ro	le of					$r \propto and iL-18$,					
			367										 _			
	.		goia, 7-10			aı., "	Kole	от су	/tok	ines in i	nducing hype	rlipiden	าเล," <u>เ</u>	<u>liabetes 4</u>	1(Supp	<u>)</u>
		Ferra	ara,			al., '	"Graf	t-ver	sus	-host dis	sease," New 1	leg. J.	of Me	d. 324:6	67-672	!
		(199		1	01	"CL		i		_41 1.						
		low-	enei	ı., et gv a	aı., II-pro	una Itein	nges redu	ın cıı cina c	rcul diet:	ating let s," Am.	ukocytes and J. Clin. Nutr.	mitoge 54:12:	n resp 3-129	onses du (1991)	ring vei	ry-
		Geo	rge, l	Ͻ <u>.Κ.,</u>	et a	l., "Ir	ncrea	sed h	пера	atic iron	concentration	n in nor	nalcoh	olic steat	ohepati	itis is
											nterology 114					
		583	trey, (200	ט.J. ס(ט)	, et a	iι., ¨Γ	NK I	cells:	rac	cts, tunc	ctions and fall	acies,"	Immu	noi. Loda	<u>y 21</u> :5	/3-
		Harr	ison,	S.A							n C in the Tre					
											I, Placebo-Cor		Clinic	al Trial.	Д.	
EXAMINER		riell	111111111111111111111111111111111111111	y ME	port	, <u>ua</u>	5006	T			/11332 (2002) ISIDERED					
	1	1 !#	.i.a *					41-								
line through	i initia citatio	ม IT C n if n	ntatio	טט פט	nside form	ance	wne	not o	or n	iot citati	on is in confo Include copy	rmance	form	MPEP 60	9; Drav	w
communicati						۵						01 11113	101111	WILLI HEX	•	

Sheet <u>11</u> of <u>13</u> Form PTO-1449 U.S. Department of Commerce Atty. Docket No. Serial No. 10/676,045 ENZ-63(CIP) (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE CITATION cose several sheets if necessary) Applicants: Ilan, et al Filed: Sep. 30, 2003 Group: Not yet known **U.S. PATENT DOCUMENTS** FILING DATE IF **EXAMINER** SUB APPRO-CLASS CLASS INITIAL **DOCUMENT NUMBER** DATE NAME PRIATE FOREIGN PATENT DOCUMENTS TRANS-LATION SUB DOCUMENT NUMBER DATE NAME **CLASS** YES NO CLASS OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Hotamisligil, G.S., et al., "Adipose expression of tumor necrosis factor-[alpha]: direct role in obesity-linked insulin resistance," Science 259:87-91 (1993) Hotamisligil, G.S., "The role of TNFalpha and TNF receptors in obesity and insulin resistance," J. Internal Med. 245:621-625 (1999) Howard, J.K., et al., "Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice," J. Clin. Invest. 104:1051-1059 (1999) Hruszkewycz, A.M., et al., "Evidence for mitochondrial DNA damage by lipid peroxidation," Biochem. Biophys. Res. Commun. 153:191-197 (1988) Koffler, M., et al., "Immunobiological consequence of regulation of insulin receptor on alloactivated lymphocytes in normal and obese subjects," Diabetes 40:364-370 (1991) Krishnan, E.., et al., "Study of function and maturation of monocytes in morbidly obese individuals," <u>J. Surg. Res. 33</u>:89-97 (1982) Li, Z., et al., "Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system," Gastroenterology 123:1304-1310 (2002) Loffreda, S., et al., "Leptin regulates proinflammatory immune responses," FASEB J 12:57-Lord, G.M., et al., "Leptin-modulates the T-cell immune response and reverses starvationinduced immunosuppression," Nature 394:897-901 (1998) Mattacks, C.A., et al., "Interactions of noradrenalin and tumour necrosis factor alpha, interleukin 4 and interleukin 6 in the control of lipolysis from adipocytes around lymph nodes," Cytokine 11:334-346 (1999) Matteoni, C.A., et al., "Nonalcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological Severity," Gastroenterology 116:1413 (1999) **EXAMINER DATE CONSIDERED** *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

													<u>neet </u>	_120	† <u> </u>	
Form PTO-14	49 L	J.S. D	epar	tmer	t of	Com	merc	е		•	Docket No.		Seria	al No. 10	676,0	45
(REV. 8-83)	Pate	nt an	d Tra	dem	ark C	ffice	<u> </u>			ENZ-6	33(CIP)					
INFOF									'							
O LE Fan	se se	veral	shee	ts if	nece	ssary	/ }		-	A 1: -						
/	1								2	Applica	ants: llan, et al					•
JAN 2 6 200	4 (3)														·	
漫										Filed:	Sep. 30, 2003		Grou	ıp: Not	yet kn	own
TRADEMA	3t /						11.5	DATI	ENT	DOCIII	MENTS					<u> </u>
		1	·				0.3.	FAII		DOCO	VIEWIS	/		T	FILII	NG
																TE IF
EXAMINER													LASS	SUB		PRO-
INITIAL		DO	<u>CUM</u>	ENT	NUN	IBER	·	т	DA	ATE	NAME			CLASS	PRIA	ATE
															1 .	
ı	,	1.		1	l	, FC	REIC	N PA	YTEN	NT DOC	UMENTS	I		i	1	
											Ī					
															TRAN	
		DO	симі	ENT I	NUM	BER			DA	ATE	NAME	CLA		SUB CLASS	<u>LATIC</u> YES	NO NO
											"""	CLA	155	32,100		.,0
					,											
} i		I i OTH	I IER D	ocu	IMEN	ITS (Inclu	dina .	Í A⊔th	nor Titl	l e, Date, Pertine	 ent Par	nes F	tc)		
											difference and				c resor	nance
			jing t 2 (19		iques	s in a	nima	ıls, pl	hant	oms an	d humans: fatt	y liver	," <u>Inve</u>	est. Radio	ol. 26:1	1041-
					T., e	t al.,	"Dep	ot-re	late	d gene	expression in h	uman	subcu	ıtaneous	and or	nental
										(1998						
											e in bone marro miallogeneic mo				-	s
								(200		111 0 30	manogenere me	Juse 11	iodei,	DOILE IV	arrovv	
											s factor and int					
											vity and intrace 5 (1989)	llular l	ipolys	is in 3T3	-L1 cel	ls,"
· · · · · · · · · · · · · · · · · · ·											bese gene prode	uct on	body	weight r	egulati	ion in
		ob/o	b mic	ce," 🤄	Scier	<u>ce 2</u>	<u>69</u> :5	40-5	43 (1995)	_			_		
								rm ch	nang	es in a	dipose tissue in	huma	n dise	ase," Pro	c. Nut	<u>r.</u>
		Soc.						00 =	•:. ::-	h. c = -1 '	ntorio dia C					•
											nterleukin-6 pro 0:3052-3058 (1		אם חכ	normal a	na mai	ignant
											nt factor D activ		n imm	une-relat	ed defe	ect in
		obes	ity,"	<u>Scie</u>	nce 2	<u> 244:</u>	1483	-148	7 (1	989)	-				•	•
											atitis: associati				ice and	1.
											gy 120:1183-1 cute Inflammatio				in Love	ale:
											Exp. Med. 185				III LEVE	715.
EXAMINER	<u> </u>										ISIDERED		<u></u>	•		
*EXAMINED	Initis	al if c	itatio	n cc	neide	red	whe	ther	or 00	ot citati	on is in conform	nanco	with	MDED 60	Q. Dro	w line
through citat										טונמנו או והבו	OU IS III COMIOM	ı lalıce	WILD.	IVIFEF 6U	ອ, Dra	w iine

Form PTO-1449 U.S. Department of Commerce										Atty. Docket No.			Serial No. 10/676,045			
(REV. 8-83) Patent and Trademark Office										ENZ-63(CIP)						
<u>IN</u> FORMATION DISCLOSURE CITATION										· .						
P E(use several sheets if necessary)																
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1									Applica	Applicants: Ilan, et al						
JAN 2 6 2004 (5)																
JAN 2 - ES									Filed:	Filed: Sep. 30, 2003			Group: Not yet known			
A TO LOCAL	<u> </u>								DOGUMENTO							
Filed: Sep. 30, 2003 Group: Not yet known U.S. PATENT DOCUMENTS FILING															iiG	
														DATE IF		
EXAMINER		DOCUMENT AUTABES							DATE			LASS	SUB CLASS	APPRO- PRIATE		
INITIAL		DOCUMENT NUMBER								NAME			- CEASS			
						ļ										
							1									
FOREIGN PATENT DOCUMENTS																
														TRANS-		
		DOCUMENT NUMBER											SUB	LATION YES NO		
									DATE	NAME	CLA	SS	CLASS			
								-								
											_					
									<u> </u>	1			<u>,</u>			
	1 1	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Shilobet, O., et al., "NKT and CD8 lymphocytes mediate suppression of hepatocellular														
		carcinoma growth via tumor antigen-pulsed dendritic cells," Int. J. Cancer 106 :236-243 (2003) Taylor, P.A., et al., "The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality," Blood 99 :3493-3499 (2002)														
		Tomohiro, N., et al., "Aromatase activity and interleukin-6 production by normal and malignant breast tissues," Radiology 218:642-646 (2001)														
		Trop, S., et al., "NK 1.1 + T Cell: A Two-Faced Lymphocyte in Immune Modulation of the														
	IL-4/IFN- Paradigm," J. Clin. Immunol. 22:270-280 (2002)															
		Uysal, K.T., et al., "Protection from obesity-induced insulin resistance in mice lacking Tnf-alpha function," Nature 389:610-614 (1997)														
	\vdash	Vogelsang, G.B., et al., "Graft versus host disease: Implications from basic immunology for														
,		prophylaxis and treatment," <u>Cancer Treat. Res. 77</u> :87-97 (1997)														
	ľ	Yang, et al., "Obesity increases sensitivity to endotoxin liver injury: Implications for the														
		pathogenesis of steatohepatitis," <u>Proc. Natl. Acad. Sci USA 94</u> :2557-2562 (1997) Zeng, D., et al., "Bone Marrow NK1.1" and NK1.1 + T Cells Reciprocally Regulate Acute														
		Graft versus Host Disease," J. Exp. Med. 189:1073-1081 (1999)														
		Zhang, Y., et al., "Positional cloning of the mouse obese gene and its human homologue," Nature 372:425-432 (1994)														
	-	<u>Natu</u>	ire 3	<u>/2</u> :4	25-4	32 (1	994)				 .		·			
EXAMINER			/Zac	hary	Skel	ding/	<i>'</i>	Ť	DATE CON	ISIDERED	(08/12/	2008			
*EXAMINER:	Initia	al if c	itatio	on co	nside	ered.	whe	ther o	or not citati	on is in confor	mance	with	MPEP 60	9: Drav	w line	
										ude copy of th						